

Figure 1. Axial T2-weighted MRI showing type b dissection flap (arrow) in the visceral abdominal aorta (a), aorta at its bifurcation (b), and in the right common iliac artery (c).



Figure 2. Coronal T2-weighted MRI showing true lumen associated with the Stanford type B dissection, and the area of infrarenal aortic stenosis (arrow).

Although the patient was not aware of any formal connective tissue disease diagnosis, it was suspected that an underlying connective tissue disease was likely in view of the combination of aortic dissection and urinary reflux, and the patient was referred for further genetic investigations which are still pending.

The patient was seen in the Interventional Radiology Outpatient Clinic, anesthetics pre-admission clinic for preparation, and pre-medicated with oral prednisolone 50 mg, two doses prior to the procedure, and oral cetirizine 10 mg, for contrast allergy. This is in line with our hospital protocol for contrast allergy pre-medication.




Figure 3. Overhill right internal iliac angiogram showing enlarged right uterine artery (arrow) and filling of the large uterine fibroid (open arrow).

The procedure was performed under intravenous conscious sedation provided by an anesthetist. Given the altered flow dynamics to the right leg, the left common femoral artery was accessed using a modified Seldinger technique and a 5-French sheath inserted. Overhill access to the right internal iliac artery was obtained with an 0.038" catheter (Rim, Merit Medical, USA) (Figure 3), followed by super selection of the uterine artery with a microcatheter (Progreat 135 cm 2.7 Fr, Terumo, Japan) and embolization with 355–500 micrometer PVA particles, in the standard manner for uterine fibroid embolisation. Given the stenotic lower abdominal aorta, a Waltman loop was felt to be difficult to perform and the rim catheter did not provide enough stability to facilitate an ipsilateral internal iliac artery approach. The catheter was, thus, changed for a dedicated uterine artery catheter (UAC2, Merit Medical, USA). Although the true lumen stenosis made this a challenge, this was able to be formed in the lower aorta and passed into the internal iliac artery (Figure 4). The




Figure 4. Ipsilateral left internal iliac artery access using UAC2 catheter (Merit Medical) and microcatheter to the uterine artery.

ipsilateral left uterine artery was then super selected with the microcatheter and also treated with PVA particles.

An Angio-Seal closure device (Terumo, Japan) was used at the conclusion to close the arteriotomy and was deployed without complication (confirmed with on-table ultrasound after deployment). The patient was discharged on day 1 post-operative with mild post-embolization syndrome [2]. At 6-week clinical follow-up, the fibroid remained avascular on transabdominal ultrasound and the patient reports improvement in menorrhagia. The patient otherwise remains clinically silent to any further vascular abnormalities.

Discussion

Patients with a history of aortic dissection are a challenging population for the endovascular proceduralist. Frequently, interventional angiography, including UAE is considered relatively unsuitable in patients with CTD [7,8]. However, there is a lack of evidence to guide treatment approach to symptomatic uterine fibroid in this population. Indeed, to our knowledge, no prior case reports describing UAE in a patient with CTD are available and we acknowledge that treatment via open (hysterectomy or myomectomy) or endovascular approaches in this complex patient presented a risk with either approach.

In the general population, UAE offers a safe, effective, and economical alternative to medical or surgical management in the treatment of symptomatic uterine fibroids with similar improvement in quality of life at 5 years

after treatment in either surgical or UAE groups, and with fewer major complications. This is offset by more minor complications and a greater need for re-intervention at 10 years after treatment [1,2,8,9].

Although there is limited literature on the subject, it is reasonable to assume that both UAE and surgery are associated with higher rates of complications in patients with CTD. Indeed, the HOPEFUL study [1] found that “medical comorbidity” predisposed to post-operative morbidity in both patient groups, though did not investigate the impact of connective tissue disease specifically. Successful surgical management of uterine fibroid in a marfanoid patient has previously been reported [10], but there are no previous case reports of UAE in similar patients.

This case is not without points of limitation to mention. It is reasonable to consider that in this patient, at 10 months after the aortic event, the intimal flap is scarred / fibrous and indeed the catheter feedback supported this during the case with the lower aortic true lumen stenotic but firm to catheter manipulation. It is encouraging to see that catheters can be successfully looped in the aorta even with the inherent stenosis and may have been helped by the iliac-specific catheter used (UAC2, Merit Medical). An ipsilateral approach with a smaller reverse curve catheter may have been an alternative possibility in some patients with appropriate internal iliac artery size and angulation. The risk of dissection associated with femoral access, and the use of a closure device is also a concern but did not materialize in this patient. In this patient, the dissection flap made access from the right common femoral artery difficult and also removed potential for radial access, something that often benefits patients with elevated body mass index. As the flap did not involve the left iliac system, this side remained available for access and both internal iliac and uterine arteries were normal, resulting in otherwise normal delivery of embolic material once the upstream vascular obstacles were negotiated.

This case report describes successful UAE for symptomatic uterine fibroids in the setting of type B dissection and a potential diagnosis of CTD. Connective tissue disease or chronic type B dissection may not need to be a deterrent to offering this or other endovascular treatments in the non-acute setting. In particular, patients who wish to retain their uterus or who are averse to the risks of major surgery should be considered candidates for endovascular uterine treatment with appropriate counselling of the risks and benefits of both approaches.

What is new?

Uterine fibroid embolization is an established treatment for symptomatic uterine fibroids. However, it is recommended to avoid endovascular procedures in those with connective tissue disease or aortic dissection. We describe a successful case of treatment in this setting, discuss reasons, and risks of alternative treatments.

List of Abbreviations

BMI	Body mass index
CTD	Connective tissue disease
UAE	Uterine artery embolization

Consent for publication

Informed written consent was obtained from the patient in this case.

Ethical approval

For case reports, specific ethical board approval is not required at my institute if the patient has provided consent.

Author details

Eleanor Danek¹, Warren Clements^{1,2}

1. Department of Radiology, Alfred Hospital, Melbourne, Victoria, Australia
2. Department of Surgery, Monash University, Clayton, Victoria, Australia

References

1. Hirst A, Dutton S, Wu O, Briggs A, Edwards C, Waldenmaier L, et al. A multi-centre retrospective cohort study comparing the efficacy, safety and cost-effectiveness of hysterectomy and uterine artery embolisation for the treatment of symptomatic uterine fibroids. The HOPEFUL study. *Health Technol Asses*. 2008;12(5):1–248, iii. <https://doi.org/10.3310/hta12050>
2. Clements W, Ang WC, Law M, Goh GS. Treatment of symptomatic fibroid disease using uterine fibroid embolisation: an Australian Perspective. *ANZJOG*. Online early view, ahead of publication. *Australian and New Zealand Journal of Obstetrics and Gynaecology*. <https://doi.org/10.1111/ajo.13120>
3. Clements W, Moriarty HK, Koukounaras J, Joseph T, Phan T, Goh GS. The cost to perform uterine fibroid embolisation in the Australian public hospital system. *J Med Imaging Radiat Oncol*. 2020;64(1):18–22. <https://doi.org/10.1111/1754-9485.12982>
4. Pacini D, Di Marco L, Fortuna D, Belotti LM, Gabbieri D, Zussa C. Acute aortic dissection: epidemiology and outcomes. *Int J Cardiol*. 2013;167(6):2806–12. <https://doi.org/10.1016/j.ijcard.2012.07.008>
5. Müller B, Modlich O, Prisack HB, Bojar H, Schipke JD, Goecke T. Gene expression profiles in the acutely dissected human aorta. *Eur J Vasc Endovasc*. 2002;24(4):356–64. <https://doi.org/10.1053/ejvs.2002.1731>
6. Lum YW, Brooke BS, Arnaoutakis GJ, Williams TK, Black JH, III. Endovascular Procedures in Patients With Ehlers-Danlos Syndrome: A Review of Clinical Outcomes and Iatrogenic Complications. *Ann Vasc Surg*. 2012;26(1):25–33. <https://doi.org/10.1016/j.avsg.2011.05.028>
7. Semaan S. Uterine artery embolization. In: Taslakian B, Al-Kutoubi A, Hoballah JJ, editors. *Procedural dictations in image-guided intervention: non-vascular, vascular and neuro interventions*. Cham, Switzerland: Springer International Publishing; 2016. pp 525–7. https://doi.org/10.1007/978-3-319-40845-3_115
8. Martin M, Machan L. Uterine artery embolization to treat uterine fibroids. *Can Assoc Radiol J*. 2001;52(3):183.
9. Ito T, Mattingly PJ, Jan AG, Biscette SM, Kim JHJ. Alternatives to excisional therapy: a clinical review of our current options to conservatively manage symptomatic leiomyomas. *Curr Opin Obstet Gynecol*. 2018;30(4):279–86. <https://doi.org/10.1097/GCO.0000000000000470>
10. Adlan A-S, Singh J, Adenan N. Case study: the subfertility management of a marfanoid patient: FC 6.06. *J Obstet Gynaecol Res*. 2015;41.

Summary of the case

1	Patient (gender, age)	Female, 44
2	Final diagnosis	Uterine fibroids and Type B aortic dissection
3	Symptoms	Heavy menstrual bleeding, pain
4	Medications	N/A
5	Clinical procedure	Angiogram, embolization
6	Specialty	Gynecology, interventional radiology